Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

2.

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.

McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM.

Biochim Biophys Acta. 2016 Dec;1863(12):2942-2976. doi: 10.1016/j.bbamcr.2016.09.004. Epub 2016 Sep 6. Review.

3.

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J.

Hepatology. 2007 Jan;45(1):42-52.

PMID:
17187432
4.

Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.

Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K, Natrajan R.

J Pathol. 2016 Nov;240(3):315-328. doi: 10.1002/path.4778.

5.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

6.

Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.

Edmunds SC, Kelsell DP, Hungerford JL, Cree IA.

Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2845-51.

PMID:
12202501
7.

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.

Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R.

JAMA Oncol. 2016 Dec 1;2(12):1565-1573. doi: 10.1001/jamaoncol.2016.0891.

PMID:
27388585
8.

TGF-β upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability.

Liu WT, Huang KY, Lu MC, Huang HL, Chen CY, Cheng YL, Yu HC, Liu SQ, Lai NS, Huang HB.

Oncogene. 2017 May 11;36(19):2715-2723. doi: 10.1038/onc.2016.424. Epub 2016 Nov 28.

9.

The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.

Ng CKY, Piscuoglio S, Geyer FC, Burke KA, Pareja F, Eberle CA, Lim RS, Natrajan R, Riaz N, Mariani O, Norton L, Vincent-Salomon A, Wen YH, Weigelt B, Reis-Filho JS.

Clin Cancer Res. 2017 Jul 15;23(14):3859-3870. doi: 10.1158/1078-0432.CCR-16-2857. Epub 2017 Feb 2.

10.

Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.

Hamilton MP, Rajapakshe K, Hartig SM, Reva B, McLellan MD, Kandoth C, Ding L, Zack TI, Gunaratne PH, Wheeler DA, Coarfa C, McGuire SE.

Nat Commun. 2013;4:2730. doi: 10.1038/ncomms3730.

11.

Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.

Gaujoux S, Tissier F, Groussin L, Libé R, Ragazzon B, Launay P, Audebourg A, Dousset B, Bertagna X, Bertherat J.

J Clin Endocrinol Metab. 2008 Oct;93(10):4135-40. doi: 10.1210/jc.2008-0631. Epub 2008 Jul 22.

PMID:
18647815
12.

Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail.

Moon H, Ju HL, Chung SI, Cho KJ, Eun JW, Nam SW, Han KH, Calvisi DF, Ro SW.

Gastroenterology. 2017 Nov;153(5):1378-1391.e6. doi: 10.1053/j.gastro.2017.07.014. Epub 2017 Jul 20.

PMID:
28734833
13.

Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.

Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H.

Int J Cancer. 2003 Sep 1;106(3):334-41.

14.

Identification of druggable cancer driver genes amplified across TCGA datasets.

Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, Hamm N, Ma X, Higgs RE, Bhagwat SV, Buchanan S, Peng SB, Staschke KA, Yadav V, Yue Y, Kouros-Mehr H.

PLoS One. 2014 May 29;9(5):e98293. doi: 10.1371/journal.pone.0098293. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107646.

15.

The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.

Patel SJ, Trivedi GL, Darie CC, Clarkson BD.

J Cell Mol Med. 2017 Mar;21(3):456-466. doi: 10.1111/jcmm.12989. Epub 2016 Sep 29.

16.

Automated network analysis identifies core pathways in glioblastoma.

Cerami E, Demir E, Schultz N, Taylor BS, Sander C.

PLoS One. 2010 Feb 12;5(2):e8918. doi: 10.1371/journal.pone.0008918.

17.

Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production.

Ladelfa MF, Toledo MF, Laiseca JE, Monte M.

Antioxid Redox Signal. 2011 Sep 15;15(6):1749-61. doi: 10.1089/ars.2010.3652. Epub 2011 Apr 14. Review.

PMID:
20919943
18.

Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.

Song CQ, Li Y, Mou H, Moore J, Park A, Pomyen Y, Hough S, Kennedy Z, Fischer A, Yin H, Anderson DG, Conte D Jr, Zender L, Wang XW, Thorgeirsson S, Weng Z, Xue W.

Gastroenterology. 2017 Apr;152(5):1161-1173.e1. doi: 10.1053/j.gastro.2016.12.002. Epub 2016 Dec 10.

19.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

20.

Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.

Labbé E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L.

Cancer Res. 2007 Jan 1;67(1):75-84.

Supplemental Content

Support Center